Premier Alternatives

Nuwacell

Biotech · Hefei, Anhui · Founded 2016 · Privately Held (backing)

Developer of cell therapy products designed for Induced Pluripotent Stem Cells (iPSC). Nuwacell is based in Hefei, Anhui and was founded in 2016. Its last reported valuation was $203 million in Jun 2022. It has raised $63.7 million across 2 recorded rounds; the latest was an $11.6 million Series B (final close) in Apr 2025.

Last reported valuation
$202.5M
Oct 2026
Priced at
—
Total raised
$63.7M
Last round
Series B (final close)
Apr 2025

Nuwacell key facts

as of Oct 2026
  • Developer of cell therapy products designed for Induced Pluripotent Stem Cells (iPSC).
  • Nuwacell is valued at approximately $202.5M as of Oct 2026 (last reported valuation).
  • It has raised $63.7M across 2 recorded rounds; the latest was Series B (final close) ($11.6M) in Apr 2025.
  • Notable investors include Hefei Industry Investment Group, Legend Capital, Hefei Hi-Tech VC, GF Xinde Investment Management, Shanghai Jiao Tong University Foundation — 11 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$202.5M

Nuwacell's last reported valuation, Jun 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Nuwacell with a free account
  • ·The complete investor list: 11 names
  • ·Everyone on the team, board and advisors included
  • ·Watch Nuwacell: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Nuwacell funding rounds

2 rounds
Apr 2025Series B (final close)$11.6M▮
Nov 2024Series B (first close)$21.0M▮
Full funding history →

Nuwacell leadership

Nuwacell valuation

Nuwacell's last reported valuation was $203 million in Jun 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Nuwacell raised?

Nuwacell has raised $63.7 million in total; 2 of its rounds are on record. The largest on record was a $21 million Series B (first close) in Nov 2024; the most recent was an $11.6 million Series B (final close) in Apr 2025.

Nuwacell investors

11 investors are on record for Nuwacell, including Hefei Industry Investment Group, Legend Capital, Hefei Hi-Tech VC and GF Xinde Investment Management. By type, the record holds 4 venture capital firms and 1 private equity firm.

Who runs Nuwacell

6 people are listed on the Nuwacell team: 6 executives, including Junying Yu (Founder) and Ying Zhang (Founder).

Comparable companies

Comparable biotech names by valuation on PrivateMarketView: Chai Discovery ($1.3 billion), Merida Biosciences ($228 million) and InduPro ($125 million).

About Nuwacell

Developer of cell therapy products designed for Induced Pluripotent Stem Cells (iPSC). The company's products have systematically built a patent portfolio around iPSC technology applications, covering iPSC reprogramming, as well as induced differentiation, roduction processes and key raw materials of multiple functional cells, enabling patients with regenerative medicine and disease treatment.

Industry
Biotech
Sector
Healthcare
HQ
Hefei, Anhui, China
Founded
2016
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.